Helmy Eltoukhy Sells 50,932 Shares of Guardant Health, Inc. (NASDAQ:GH) Stock

Guardant Health, Inc. (NASDAQ:GH) CEO Helmy Eltoukhy sold 50,932 shares of the business’s stock in a transaction that occurred on Monday, April 19th. The shares were sold at an average price of $152.97, for a total value of $7,791,068.04. Following the completion of the sale, the chief executive officer now directly owns 2,161,187 shares in the company, valued at approximately $330,596,775.39. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Helmy Eltoukhy also recently made the following trade(s):

  • On Friday, April 16th, Helmy Eltoukhy sold 51,123 shares of Guardant Health stock. The shares were sold at an average price of $158.34, for a total value of $8,094,815.82.
  • On Wednesday, April 14th, Helmy Eltoukhy sold 60,982 shares of Guardant Health stock. The shares were sold at an average price of $156.54, for a total value of $9,546,122.28.
  • On Monday, April 12th, Helmy Eltoukhy sold 72,861 shares of Guardant Health stock. The stock was sold at an average price of $154.59, for a total transaction of $11,263,581.99.
  • On Friday, April 9th, Helmy Eltoukhy sold 60,996 shares of Guardant Health stock. The shares were sold at an average price of $156.86, for a total transaction of $9,567,832.56.
  • On Wednesday, April 7th, Helmy Eltoukhy sold 36,843 shares of Guardant Health stock. The stock was sold at an average price of $158.61, for a total transaction of $5,843,668.23.
  • On Monday, January 25th, Helmy Eltoukhy sold 58,811 shares of Guardant Health stock. The shares were sold at an average price of $157.26, for a total transaction of $9,248,617.86.
  • On Thursday, January 21st, Helmy Eltoukhy sold 173,206 shares of Guardant Health stock. The stock was sold at an average price of $162.01, for a total value of $28,061,104.06.
  • On Tuesday, January 19th, Helmy Eltoukhy sold 103,717 shares of Guardant Health stock. The shares were sold at an average price of $160.12, for a total value of $16,607,166.04.

Shares of NASDAQ GH opened at $149.47 on Wednesday. The business has a 50-day moving average price of $147.50 and a 200 day moving average price of $135.77. The stock has a market cap of $15.01 billion, a PE ratio of -78.26 and a beta of 0.57. Guardant Health, Inc. has a 52-week low of $71.41 and a 52-week high of $181.07.

Guardant Health (NASDAQ:GH) last posted its earnings results on Wednesday, February 24th. The company reported ($0.94) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.44) by ($0.50). Guardant Health had a negative return on equity of 19.22% and a negative net margin of 67.14%. The firm had revenue of $78.32 million for the quarter, compared to analysts’ expectations of $77.75 million. As a group, research analysts forecast that Guardant Health, Inc. will post -2.09 EPS for the current year.

GH has been the topic of several recent research reports. Morgan Stanley upped their price target on Guardant Health from $130.00 to $175.00 and gave the stock an “overweight” rating in a report on Thursday, March 4th. Stifel Nicolaus began coverage on shares of Guardant Health in a research note on Monday, January 11th. They set a “buy” rating and a $175.00 target price on the stock. SVB Leerink lifted their price target on shares of Guardant Health from $150.00 to $190.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 20th. Canaccord Genuity reissued a “buy” rating and issued a $195.00 price objective on shares of Guardant Health in a research report on Thursday, February 25th. Finally, Zacks Investment Research upgraded shares of Guardant Health from a “sell” rating to a “hold” rating in a report on Wednesday, February 24th. One investment analyst has rated the stock with a hold rating and nine have given a buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $166.09.

Several large investors have recently added to or reduced their stakes in the stock. Hudson Value Partners LLC grew its position in shares of Guardant Health by 22.0% during the first quarter. Hudson Value Partners LLC now owns 9,128 shares of the company’s stock worth $1,393,000 after buying an additional 1,646 shares in the last quarter. Carnegie Capital Asset Management LLC grew its holdings in Guardant Health by 5.5% during the 1st quarter. Carnegie Capital Asset Management LLC now owns 100,205 shares of the company’s stock worth $15,296,000 after acquiring an additional 5,238 shares in the last quarter. Valeo Financial Advisors LLC increased its position in shares of Guardant Health by 4.6% in the 1st quarter. Valeo Financial Advisors LLC now owns 1,702 shares of the company’s stock worth $260,000 after purchasing an additional 75 shares during the last quarter. Koshinski Asset Management Inc. acquired a new stake in shares of Guardant Health in the 4th quarter valued at about $813,000. Finally, Defined Wealth Management LLC bought a new position in shares of Guardant Health during the fourth quarter worth about $64,000. Institutional investors and hedge funds own 84.85% of the company’s stock.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients.

Recommended Story: How can you know how many shares are floating?

Insider Buying and Selling by Quarter for Guardant Health (NASDAQ:GH)

Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.